In the setting of CAR-CD19 T cells secreting bridging proteins, CD19 expressed on normal B cells will be a readily accessed antigen source, to allow immunologically relevant CAR T cell expansion and to enhance persistence regardless of the targeted tumor antigen and indication. The gene discussed is CD19; the disease is neoplasm.